贝伐单抗联合化疗治疗复发高级别胶质瘤的疗效观察及安全性分析

Analysis of efficacy and safety of bevacizumab combined with chemotherapy in treatment of recurrent high grade gliomas

目的分析贝伐单抗联合化疗治疗复发高级别胶质瘤的疗效观察及安全性。方法选取天津医科大学宝坻临床学院2015年2月～2017年6月收治的50例复发高级别胶质瘤患者为研究对象。对照组给予常规化疗治疗，实验组在此基础上给予贝伐单抗，10mg/kg，2周1次，静脉滴注。比较分析实验组与对照组患者的临床疗效及不良反应等临床指标。结果治疗后，实验组治疗有效率80.0%，显著高于对照组有效率为68.0%（P＜0.05）。实验组与对照组患者均未发生严重不良反应，对照组与实验组发生白细胞减少、恶心呕吐及贫血等不良反应概率并无显著差异。结论贝伐单抗联合化疗治疗复发高级别胶质瘤的疗效较为理想，可显著改善临床症状，控制病情，安全性较高，均耐受。

Objective To analyze the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of recurrent highgrade gliomas.Methods50cases admitted to our hospital with recurrent high grade gliomas patients from February2015to June2017as the research object.The control group was treated with chemotherapy,and the experimental group was given bevacizumab,10mg/kg,2times a week,intravenous drip.A comparative analysis of the experimental group and the control group of patients with clinical indicators of clinical efficacy and adverse reaction etc.Results The effective rate of the experimental group was80%,significantly higher than68%of the control group,(P<0.05).There were no serious adverse reactions in the experimental group and the control group,and there was no significant difference in the incidence of adverse reactions such as WBC,nausea,vomiting and anemia between the control group and the experimental group.Conclusion The curative effect of bevacizumab combined with chemotherapy in the treatment of recurrent high-grade glioma is ideal.It can significantly improve the clinical symptoms,control the disease,and has high safety and tolerance.